Drugs / BI 3706674
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06056024 | Dec 2023 → Dec 2025 | — | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 3706674 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06056024 ↗ |
| Action | Inhibit | “BI 3706674 blocks growth signals and may prevent the tumour from growing.” NCT06056024 ↗ |
| Route | Oral | “BI 3706674 Given Orally as Monotherapy” NCT06056024 ↗ |